Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for PVP-I  COVID-19 treatment studies for Povidone-Iod..  C19 studies: Povidone-Iod..  Povidone-Iod..   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Melatonin (meta)
Aspirin (meta) Metformin (meta)
Bamlaniv../e.. (meta) Molnupiravir (meta)
Bebtelovimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Cannabidiol (meta) Nitric Oxide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Lactoferrin (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Viral load 34% no CI Improvement Relative Risk Viral load (b) 50% no CI c19pvpi.com Sánchez Barrueco et al. NCT04707742 Povidone-Iod.. RCT LATE Favors povidone-iodine Favors control
Sánchez Barrueco, 75 patient povidone-iodine late treatment RCT: 34% improved viral load https://c19p.org/sanchezbarrueco
copied to clipboard
Effect of oral antiseptics in reducing SARS-CoV-2 infectivity: evidence from a randomized double-blind clinical trial
Sánchez Barrueco et al., Emerging Microbes & Infections, doi:10.1080/22221751.2022.2098059, NCT04707742 (history)
27 Jul 2022    Source   PDF   Share   Tweet
RCT hospitalized patients testing viral load shortly after a single mouthwash with PVP-I, hydrogen peroxide, cetylpyridinium chloride, chlorhexidine, and water. For PVP-I, there were only 5 patients with viable virus at baseline. Cross-treatment comparisons are limited due to the very small sample sizes and large difference between baseline viral loads (the baseline viral culture non-log copies/mL was ~10,000 times higher in the water group vs. PVP-I).
The trial registration shows that 160 patients were recruited, with 62 patients added in an October 6, 2021 change, however the paper presents results for only 75 patients.
risk of viral load, 33.9% lower, RR 0.66, treatment 5, control 5, relative viral culture non-log median copies/mL, 60 minutes vs. baseline.
risk of viral load, 49.9% lower, RR 0.50, treatment 5, control 5, relative viral culture non-log median copies/mL, 30 minutes vs. baseline.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sánchez Barrueco et al., 7/27/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Spain, peer-reviewed, mean age 55.0, 17 authors, trial NCT04707742 (history).
Contact: mira_ale@gva.es.
All Studies   Meta Analysis
This PaperPovidone-Iod..All
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit